Top

Published in:

Open Access 19-10-2023 | Expert Opinion

Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts

Authors: Daniele Santini, Giuseppe Luigi Banna, Sebastiano Buti, Luca Isella, Marco Stellato, Michela Roberto, Roberto Iacovelli

Published in: Current Oncology Reports | Issue 11/2023

Abstract

Purpose of Review

To discuss recent advances in the treatment of advanced urothelial carcinoma (UC) and how best to incorporate new therapies into clinical practice.

Recent Findings

There have been several recent practice-changing phase 2 and 3 trials of immune checkpoint inhibitors (ICIs), antibody–drug conjugates (ADCs), and targeted agents in advanced UC. Based on data from these trials, ICIs can be used as first-line maintenance therapy in patients who do not progress on platinum-based chemotherapy, second-line therapy for those with progression, and first-line therapy in cisplatin-ineligible patients with PD-L1 expression; ADCs and targeted agents provide later-line treatment options.

Summary

Despite substantial progress in the treatment of advanced UC, there are still many uncertainties, including the optimal treatment sequence for novel agents, and reliable predictive biomarkers to aid in treatment selection. There is also an unmet need for effective treatment options in patients unfit for any platinum-based chemotherapy.

Cassell A 3rd, Manobah B, Willie S. Diagnostic and therapeutic challenges of rare urogenital cancers: urothelial carcinoma of the renal pelvis, ureters and urethra. World J Oncol. 2021;12(1):20–7. https://doi.org/10.14740/wjon1360.CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.CrossRefPubMed

Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24(10):730–4. https://doi.org/10.1111/iju.13376.CrossRefPubMed

Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021;79(1):62–79. https://doi.org/10.1016/j.eururo.2020.05.042.CrossRefPubMed

Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol. 2016;70(3):458–66. https://doi.org/10.1016/j.eururo.2015.06.042.CrossRefPubMed

van Doeveren T, van de Werken HJG, van Riet J, Aben KKH, van Leeuwen PJ, Zwarthoff EC, et al. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: are they clonally related? A systematic review Urol Oncol. 2020;38(6):590–8. https://doi.org/10.1016/j.urolonc.2020.01.008.CrossRefPubMed

Cathomas R, Lorch A, Bruins HM, Comperat EM, Cowan NC, Efstathiou JA, et al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur Urol. 2022;81(1):95–103. https://doi.org/10.1016/j.eururo.2021.09.026.CrossRefPubMed

Chester JD. Unifying themes in urothelial cancers. Eur Urol. 2021;79(1):80–1. https://doi.org/10.1016/j.eururo.2020.09.045.CrossRefPubMed

Meireles S, Dias N, Martins D, Dias C, Gonçalves M, Silva J, et al. Prognostic value of bladder involvement in the outcome of upper tract urothelial carcinoma. Diagnostics (Basel). 2023;13(1):153. https://doi.org/10.3390/diagnostics13010153.CrossRefPubMed

10.

Aragon-Ching JB, Werntz RP, Zietman AL, Steinberg GD. Multidisciplinary management of muscle-invasive bladder cancer: current challenges and future directions. Am Soc Clin Oncol Educ Book. 2018;38:307–18. https://doi.org/10.1200/EDBK_201227.CrossRefPubMed

11.

Dobruch J, Oszczudlowski M. Bladder cancer: current challenges and future directions. Medicina (Kaunas). 2021;57(8):749. https://doi.org/10.3390/medicina57080749.CrossRefPubMedPubMedCentral

12.

Ghandour R, Singla N, Lotan Y. Treatment options and outcomes in nonmetastatic muscle invasive bladder cancer. Trends Cancer. 2019;5(7):426–39. https://doi.org/10.1016/j.trecan.2019.05.011.CrossRefPubMed

13.

Stecca C, Abdeljalil O, Sridhar SS. Metastatic urothelial cancer: a rapidly changing treatment landscape. Ther Adv Med Oncol. 2021;13:17588359211047352. https://doi.org/10.1177/17588359211047352.CrossRefPubMedCentral

14.

National Cancer Institute (NCI), National Institutes of Health (NIH). Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: bladder cancer; 2002. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed 14 April 2023.

15.

Flaig TW, Spiess PE. NCCN clinical practice guidelines in oncology: bladder cancer Version 3.2023; 2023. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed 19 July 2023.

16.

Bellmunt J, Mottet N, De Santis M. Urothelial carcinoma management in elderly or unfit patients. EJC Suppl. 2016;14(1):1–20. https://doi.org/10.1016/j.ejcsup.2016.01.001.CrossRefPubMedPubMedCentral

17.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211–4. https://doi.org/10.1016/s1470-2045(10)70275-8.CrossRefPubMed

18.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432–8. https://doi.org/10.1200/jco.2011.34.8433.CrossRefPubMed

19.

Russell BM, Boussi L, Bellmunt J. Management of advanced urothelial carcinoma in older and frail patients: have novel treatment approaches improved their care? Drugs Aging. 2022;39(4):271–84. https://doi.org/10.1007/s40266-022-00933-2.CrossRefPubMed

20.

Gupta S, Bellmunt J, Plimack ER, Sonpavde GP, Grivas P, Apolo AB, et al. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC) [ASCO abstract]. J Clin Oncol. 2022;40(16_Suppl):4577. https://doi.org/10.1200/JCO.2022.40.16_suppl.4577.CrossRef

21.

Bukhari N, Al-Shamsi HO, Azam F. Update on the treatment of metastatic urothelial carcinoma. ScientificWorldJournal. 2018;2018:5682078. https://doi.org/10.1155/2018/5682078.CrossRefPubMedPubMedCentral

22.

De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–9. https://doi.org/10.1200/JCO.2011.37.3571.CrossRefPubMed

23.

Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134–41. https://doi.org/10.1016/j.eururo.2006.12.029.CrossRefPubMed

24.

von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77. https://doi.org/10.1200/JCO.2000.18.17.3068.CrossRefPubMed

25.

von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8. https://doi.org/10.1200/JCO.2005.07.757.CrossRefPubMed

26.

Franza A, Pirovano M, Giannatempo P, Cosmai L. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations. Future Oncol. 2022;18(19):2455–64. https://doi.org/10.2217/fon-2021-1151.CrossRefPubMed

27.

D’Angelo A, Chapman R, Sirico M, Sobhani N, Catalano M, Mini E, et al. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. Cancer Chemother Pharmacol. 2022;90(3):191–205. https://doi.org/10.1007/s00280-022-04459-7.CrossRefPubMedPubMedCentral

28.

Katims AB, Reisz PA, Nogueira L, Truong H, Lenis AT, Pietzak EJ, et al. Targeted therapies in advanced and metastatic urothelial carcinoma. Cancers (Basel). 2022;14(21):5431. https://doi.org/10.3390/cancers14215431.CrossRefPubMed

29.

Maas M, Stuhler V, Walz S, Stenzl A, Bedke J. Enfortumab vedotin - next game-changer in urothelial cancer. Expert Opin Biol Ther. 2021;21(7):801–9. https://doi.org/10.1080/14712598.2021.1865910.CrossRefPubMed

30.

Mantia CM, Sonpavde G. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma. Expert Rev Anticancer Ther. 2022;22(5):449–55. https://doi.org/10.1080/14737140.2022.2069563.CrossRefPubMed

31.

Mathew Thomas V, Tripathi N, Agarwal N, Swami U. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Expert Rev Anticancer Ther. 2022;22(4):335–41. https://doi.org/10.1080/14737140.2022.2049763.CrossRefPubMed

32.

Muilwijk T, Akand M, Van der AAF, Dumez H, De Meerleer G, Van Raemdonck D, et al. Metastasectomy of oligometastatic urothelial cancer a single-center experience. Transl Androl Urol. 2020;9(3):1296–305. https://doi.org/10.21037/tau-19-624.CrossRefPubMedPubMedCentral

33.

Ogihara K, Kikuchi E, Watanabe K, Kufukihara R, Yanai Y, Takamatsu K, et al. Can urologists introduce the concept of “oligometastasis” for metastatic bladder cancer after total cystectomy? Oncotarget. 2017;8(67):111819–35. https://doi.org/10.18632/oncotarget.22911.CrossRefPubMedPubMedCentral

34.

Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81. https://doi.org/10.1200/jco.1999.17.10.3173.CrossRef

35.

Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, et al. The role of surgery in metastatic bladder cancer: a systematic review. Eur Urol. 2018;73(4):543–57. https://doi.org/10.1016/j.eururo.2017.09.030.CrossRefPubMed

36.

Berghen C, Joniau S, Vulsteke C, Albersen M, Devos G, Rans K, et al. Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. Ecancer. 2020;14:1036. https://doi.org/10.3332/ecancer.2020.1036.CrossRef

37.

Longo N, Celentano G, Napolitano L, La Rocca R, Capece M, Califano G, et al. Metastasis-directed radiation therapy with consolidative intent for oligometastatic urothelial carcinoma: a systematic review and meta-analysis. Cancers (Basel). 2022;14(10):2373. https://doi.org/10.3390/cancers14102373.CrossRefPubMedPubMedCentral

38.

Tey J, Ho F, Koh WY, Chia D, Ooi KH, Tuan JKL, et al. Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis. Acta Oncol. 2021;60(5):635–44. https://doi.org/10.1080/0284186X.2021.1880025.CrossRefPubMed

39.

Leonetti A, D’Abbiero N, Baldari G, Andreani S, Ruffini L, Viansone AA, et al. Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: a retrospective case series. Int J Urol. 2018;25(10):879–86. https://doi.org/10.1111/iju.13773.CrossRefPubMed

40.

Miranda AF, Howard JM, McLaughlin M, Meng X, Clinton T, Sanli O, et al. Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. Urol Oncol. 2021;39(11):790 e1-e7. https://doi.org/10.1016/j.urolonc.2021.05.005.CrossRefPubMed

41.

Franzese C, Francolini G, Nicosia L, Alongi F, Livi L, Scorsetti M. Stereotactic body radiation therapy in the management of oligometastatic and oligoprogressive bladder cancer and other urothelial malignancies. Clin Oncol (R Coll Radiol). 2021;33(1):50–6. https://doi.org/10.1016/j.clon.2020.07.008.CrossRefPubMed

42.

Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere P, Fonteyne V, et al. Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur Urol. 2019;75(5):707–11. https://doi.org/10.1016/j.eururo.2019.01.009.CrossRefPubMed

43.

Sindhu KK, Nehlsen AD, Lehrer EJ, Rowley JP, Stock RG, Galsky MD, et al. Oligoprogression of solid tumors on immune checkpoint inhibitors: the impact of local ablative radiation therapy. Biomedicines. 2022;10(10):2481. https://doi.org/10.3390/biomedicines10102481.CrossRefPubMedPubMedCentral

44.••

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788. The JAVELIN Bladder 100 trial was an international, phase 3 trial assessing whether avelumab maintenance therapy improved outcomes in patients with advanced urothelial carcinoma that had not progressed with first-line platinum-based chemotherapy. Maintenance avelumab and supportive care significantly prolonged overall survival compared with supportive care alone.CrossRefPubMed

45.•

Grivas P, Agarwal N, Pal S, Kalebasty AR, Sridhar SS, Smith J, et al. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: applying clinical trial findings to clinical practice. Cancer Treat Rev. 2021;97:102187. https://doi.org/10.1016/j.ctrv.2021.102187. This review summarizes the data that supported the approval of avelumab as first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma that do not progress with platinum-containing chemotherapy. Avelumab prolongs overall survival across various patient subsets, is well tolerated and should be incorporated into standard clinical practice.CrossRefPubMed

46.

Powles T, Park SH, Voog E, Caserta C, Pérez-Valderrama B, Gurney H, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up results from the JAVELIN Bladder 100 trial [ASCO abstract]. J Clin Oncol. 2022;40(6_suppl):487. https://doi.org/10.1200/JCO.2022.40.6_suppl.487.CrossRef

47.

Pérez-Valderrama B, Powles T, Sridhar SS, Caserta C, Loriot Y, Gupta S, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy [ASCO abstract]. J Clin Oncol. 2022;40(16_suppl):4559. https://doi.org/10.1200/JCO.2022.40.16_suppl.4559.CrossRef

48.

Loriot Y, Powles T, Durán MAC, Sridhar SS, Bellmunt J, Petrylak DP, et al. Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy [ASCO abstract]. J Clin Oncol. 2021;39(6_Suppl):438. https://doi.org/10.1200/JCO.2021.39.6_suppl.438.CrossRef

49.

Bellmunt J, Powles T, Climent Duran MA, Sridhar SS, Gurney H, Costa N, et al. Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: exploratory analyses from JAVELIN Bladder 100 [ASCO abstract]. J Clin Oncol. 2022;40(16_suppl):4560. https://doi.org/10.1200/JCO.2022.40.16_suppl.4560.CrossRef

50.

Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, et al. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018;124(9):2010–7. https://doi.org/10.1002/cncr.31293.CrossRefPubMed

51.

Plimack ER, Zibelman MR. Platinum-free systemic therapy in first-line metastatic urothelial carcinoma: mirage or oasis in the platinum desert? J Clin Oncol. 2022;41(1):7–10. https://doi.org/10.1200/JCO.22.01992.CrossRefPubMed

52.

Antonuzzo L, Maruzzo M, De Giorgi U, Santini D, Tambaro R, Buti S, et al. Ready: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) [ASCO abstract]. J Clin Oncol. 2023;41(6_suppl):469. https://doi.org/10.1200/JCO.2023.41.6_suppl.469.CrossRef

53.

Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107–13. https://doi.org/10.1200/jco.2011.38.6979.CrossRefPubMedPubMedCentral

54.

Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–61. https://doi.org/10.1200/jco.2008.20.5534.CrossRefPubMed

55.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. https://doi.org/10.1056/NEJMoa1613683.CrossRefPubMedPubMedCentral

56.

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22. https://doi.org/10.1016/S1470-2045(17)30065-7.CrossRefPubMed

57.••

Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023;34(3):289–99. https://doi.org/10.1016/j.annonc.2022.11.012. This analysis of the KEYNOTE-045 and -052 trials demonstrated that pembrolizumab had durable efficacy and a manageable safety profile in patients with metastatic urothelial carcinoma after 5 years of treatment, supporting the use of pembrolizumab as first- and second-line therapy.CrossRefPubMed

58.

Dang E, Vallee A, Lepage-Seydoux C, Sejean K, Bonan B, Abraham C, et al. Clinical benefit of pembrolizumab in advanced urothelial cancer patients in real-life setting: an efficacy and safety monocentric study. Curr Oncol. 2022;29(2):945–55. https://doi.org/10.3390/curroncol29020080.CrossRefPubMedPubMedCentral

59.

Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–57. https://doi.org/10.1016/S0140-6736(17)33297-X.CrossRefPubMed

60.•

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, et al. Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol. 2019;76(1):73–81. https://doi.org/10.1016/j.eururo.2019.03.015. SAUL was a multinational, single-arm, safety study of atezolizumab for locally advanced or metastatic urothelial/nonurothelial carcinoma. Atezolizumab efficacy was consistent with previous anti-PD-L1/PD-1 urothelial carcinoma trials and showed good tolerability.CrossRefPubMed

61.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. https://doi.org/10.1016/S0140-6736(16)00561-4.CrossRefPubMedPubMedCentral

62.

Sayegh N, Tripathi N, Agarwal N, Swami U. Clinical evidence and selecting patients for treatment with erdafitinib in advanced urothelial carcinoma. Onco Targets Ther. 2022;15:1047–55. https://doi.org/10.2147/OTT.S318332.CrossRefPubMedPubMedCentral

63.

Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt). J Clin Oncol. 2023;41(17_suppl):LBA4619. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA4619.CrossRef

64.•

Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–35. https://doi.org/10.1056/NEJMoa2035807. The EV-301 trial was a global, phase 3 trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-containing chemotherapy and had disease progression during or after treatment with a PD-1 or PD-L1 inhibitor. Enfortumab vedotin significantly prolonged survival compared with standard chemotherapy in this population.CrossRefPubMedPubMedCentral

65.

Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022;128(6):1194–205. https://doi.org/10.1002/cncr.34057.CrossRefPubMed

66.

Thomas J, Sonpavde G. Molecularly targeted therapy towards genetic alterations in advanced bladder cancer. Cancers (Basel). 2022;14(7):1795. https://doi.org/10.3390/cancers14071795.CrossRefPubMed

67.

Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–48. https://doi.org/10.1056/NEJMoa1817323.CrossRefPubMed

68.

Nimgaonkar V, Hubbard RA, Carpenter EL, Mamtani R. Biomarker testing, treatment uptake, and survival among patients with urothelial cancer receiving gene-targeted therapy. JAMA Oncol. 2022;8(7):1070–2. https://doi.org/10.1001/jamaoncol.2022.1167.CrossRefPubMedPubMedCentral

69.

Chehade L, Abdel Sater AH, Kourie HR, Mukherji D, Shamseddine A. Clinical implications of liquid biopsies in urogenital tumors a narrative review. Precis Cancer Med. 2022;5:24. https://doi.org/10.21037/pcm-22-1.CrossRef

70.

Vandekerkhove G, Lavoie JM, Annala M, Murtha AJ, Sundahl N, Walz S, et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun. 2021;12(1):184. https://doi.org/10.1038/s41467-020-20493-6.CrossRefPubMedPubMedCentral

71.

Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7–H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56(8):1173–82. https://doi.org/10.1007/s00262-006-0266-z.CrossRefPubMed

72.

van Wilpe S, Gerretsen ECF, van der Heijden AG, de Vries IJM, Gerritsen WR, Mehra N. Prognostic and predictive value of tumor-infiltrating immune cells in urothelial cancer of the bladder. Cancers (Basel). 2020;12(9):2692. https://doi.org/10.3390/cancers12092692.CrossRefPubMedPubMedCentral

73.

Gevaert T, Cimadamore A, Eckstein M, Scarpelli M, Lopez-Beltran A, Cheng L, et al. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. Future Oncol. 2019;15(19):2199–202. https://doi.org/10.2217/fon-2019-0217.CrossRefPubMed

74.•

Liu H, Ye T, Yang X, Lv P, Wu X, Zhou H, et al. Predictive and prognostic role of PD-L1 in urothelial carcinoma patients with anti-PD-1/PD-L1 therapy: a systematic review and meta-analysis. Dis Markers. 2020;2020:8375348. https://doi.org/10.1155/2020/8375348. This systematic review and meta-analysis evaluates the predictive/prognostic value of PD-L1 on response and survival in patients with urothelial carcinoma after undergoing cystectomy, chemotherapy, or anti-PD-1/PD-L1 therapy. PD-L1 expression in tumour-inflating immune cells shows promise as a biomarker for overall response rate and progression-free survival.CrossRefPubMedPubMedCentral

75.

Rizzo A, Mollica V, Massari F. Expression of programmed cell death ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line immune checkpoint inhibitors versus chemotherapy: a systematic review and meta-analysis. Eur Urol Focus. 2022;8(1):152–9. https://doi.org/10.1016/j.euf.2021.01.003.CrossRefPubMed

76.

Powles T, Walker J, Andrew Williams J, Bellmunt J. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treat Rev. 2020;82:101925. https://doi.org/10.1016/j.ctrv.2019.101925.CrossRefPubMed

77.

Galsky MD, Saci A, Szabo PM, Han GC, Grossfeld G, Collette S, et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275. Clin Cancer Res. 2020;26(19):5120–8. https://doi.org/10.1158/1078-0432.CCR-19-4162.CrossRefPubMedPubMedCentral

78.

Gerald T, Margulis V, Meng X, Bagrodia A, Cole S, Qin Q, et al. Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients. Urol Oncol. 2023;41(3):148 e17-e24. https://doi.org/10.1016/j.urolonc.2022.12.008.CrossRefPubMed

79.

Santopietro AL, Einstein D, Bellmunt J. Advances in the management of urothelial carcinoma: is immunotherapy the answer? Expert Opin Pharmacother. 2021;22(13):1743–59. https://doi.org/10.1080/14656566.2021.1921149.CrossRefPubMed

80.

Zhang Z, Yu Y, Zhang P, Ma G, Zhang M, Liang Y, et al. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer. BMC Cancer. 2021;21(1):458. https://doi.org/10.1186/s12885-021-08229-1.CrossRefPubMedPubMedCentral

81.

Chou J, Trepka K, Sjostrom M, Egusa EA, Chu CE, Zhu J, et al. TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells. Eur Urol Oncol. 2022;5(6):714–8. https://doi.org/10.1016/j.euo.2021.11.005.CrossRefPubMed

82.

Mollica V, Massari F, Rizzo A, Ferrara R, Menta AK, Adashek JJ. Genomics and immunomics in the treatment of urothelial carcinoma. Curr Oncol. 2022;29(5):3499–518. https://doi.org/10.3390/curroncol29050283.CrossRefPubMedPubMedCentral

83.

Scherrer E, Kang A, Bloudek LM, Koshkin VS. HER2 expression in urothelial carcinoma, a systematic literature review. Front Oncol. 2022;12:1011885. https://doi.org/10.3389/fonc.2022.1011885.CrossRefPubMedPubMedCentral

84.

Patelli G, Zeppellini A, Spina F, Righetti E, Stabile S, Amatu A, et al. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives. Cancer Treat Rev. 2022;104:102351. https://doi.org/10.1016/j.ctrv.2022.102351.CrossRefPubMed

85.

European Medicines Agency. Summary of product characteristics - Pembrolizumab; 2020. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf.

86.

Merck & Co. FDA approves updated indication for Merck’s KEYTRUDA^® (pembrolizumab) for treatment of certain patients with urothelial carcinoma (bladder cancer); 2021. https://www.merck.com/news/fda-approves-updated-indication-for-mercks-keytruda-pembrolizumab-for-treatment-of-certain-patients-with-urothelial-carcinoma-bladder-cancer/.

87.

Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15(12):3441–5. https://doi.org/10.1200/jco.1997.15.12.3441.CrossRefPubMed

88.

Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15(11):3394–8. https://doi.org/10.1200/jco.1997.15.11.3394.CrossRefPubMed

89.

Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–92. https://doi.org/10.1016/S1470-2045(17)30616-2.CrossRefPubMed

90.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. https://doi.org/10.1016/S0140-6736(16)32455-2.CrossRefPubMed

91.•

Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2022;41(1):22–31. https://doi.org/10.1200/JCO.22.01643. This ongoing phase Ib/II, multicenter, open-label study of enfortumab vedotin in first-line cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer found that enfortumab vedotin plus pembrolizumab is a promising new treatment combination.CrossRefPubMed

92.

Rosenberg JE, Milowsky M, Ramamurthy C, Mar N, McKay RR, Friedlander T, et al. LBA73. Study EV-103 Cohort K: antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) [ESMO abstract]. Ann Oncol. 2022;33(suppl_7):S1441. https://doi.org/10.1016/annonc/annonc1089.CrossRef

93.

Vuky J, Balar AV, Castellano D, O’Donnell PH, Grivas P, Bellmunt J, et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 2020;38(23):2658–66. https://doi.org/10.1200/JCO.19.01213.CrossRefPubMed

94.

Yu EY, Petrylak DP, O’Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872–82. https://doi.org/10.1016/S1470-2045(21)00094-2.CrossRefPubMed

95.

Iacovelli R, Ciccarese C, Brunelli M, Battelli N, Buttigliero C, Caserta C, et al. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. Ann Oncol. 2022;33(11):1179–85. https://doi.org/10.1016/j.annonc.2022.07.011.CrossRefPubMed

96.

Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee J-L, et al. Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma [ASCO abstract]. J Clin Oncol. 2022;40(16_suppl):4516. https://doi.org/10.1200/JCO.2022.40.16_suppl.4516.CrossRef

97.

Hanna KS, Larson S, Nguyen J, Boudreau J, Bulin J, Rolf M. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer. Am J Health Syst Pharm. 2022;79(8):629–35. https://doi.org/10.1093/ajhp/zxab464.CrossRefPubMed

98.•

Padua TC, Moschini M, Martini A, Pederzoli F, Nocera L, Marandino L, et al. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: a scoping review. Urol Oncol. 2022;40(10):413–23. https://doi.org/10.1016/j.urolonc.2022.07.006. This scoping review assesses the efficacy, treatment-related adverse events, and impact of antibody-drug conjugates on patients’ quality of life with metastatic urothelial carcinoma. Phase 2 and 3 trials suggest antibody-drug conjugates do not impact patient quality of life and improve pain symptoms but also have a high incidence of potential adverse events.CrossRefPubMed

99.

Lacouture ME, Patel AB, Rosenberg JE, O’Donnell PH. Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist. 2022;27(3):e223–32. https://doi.org/10.1093/oncolo/oyac001.CrossRefPubMedPubMedCentral

100.

US Food and Drug Administration. Padcev (enfortumab vedotin-ejfv) for injection for intravenous use: prescribing information; 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf. Accessed 13 March 2023.

101.

Wong RL, Yu EY. Enfortumab vedotin in the treatment of urothelial cancers and beyond. Future Oncol. 2022;18(27):3067–84. https://doi.org/10.2217/fon-2022-0328.CrossRefPubMed

102.

Yoon S, Shin SJ, Kim HC, Kim YS, Lee HJ, Keam B, et al. Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure. Eur J Cancer. 2022;174:81–9. https://doi.org/10.1016/j.ejca.2022.07.014.CrossRefPubMed

103.

Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Flechon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474–85. https://doi.org/10.1200/JCO.20.03489.CrossRefPubMedPubMedCentral

104.

US Food and Drug Administration. Trodelvy (sacituzumab govitecan-hziy) for injection, for intravenous use: prescribing information; 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf. Accessed 13 March 2023.

105.

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123(19):3843–54. https://doi.org/10.1002/cncr.30789.CrossRefPubMed

106.

Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746–56. https://doi.org/10.1016/j.annonc.2021.03.005.CrossRefPubMed

107.

Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A. FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice. Cancers (Basel). 2021;13(12):2968. https://doi.org/10.3390/cancers13122968.CrossRefPubMed

108.

US Food and Drug Administration. Balversa (erdafitinib) tablets, for oral use: prescribing information; 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf. Accessed 13 March 2023.

109.•

Dobry AS, Virgen CA, Hosking AM, Mar N, Doan L, Lee B, et al. Cutaneous reactions with enfortumab vedotin: a case series and review of the literature. JAAD Case Rep. 2021;14:7–9. https://doi.org/10.1016/j.jdcr.2021.05.020. This case series reports unique cutaneous reactions observed in patients with advanced urothelial carcinoma who failed platinum-based chemotherapy and immunotherapy and were treated with the antibody-drug conjugate enfortumab vedotin.CrossRefPubMedPubMedCentral

110.

Cherri S, Noventa S, Fanelli M, Calandra G, Prochilo T, Bna C, et al. Drug-related pneumonitis in cancer treatment during the COVID-19 era. Cancers (Basel). 2021;13(5):1052. https://doi.org/10.3390/cancers13051052.CrossRefPubMed

111.

Pace A, Brower B, Conway D, Leis D. Enfortumab vedotin: nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma. Clin J Oncol Nurs. 2021;25(2):E1–9. https://doi.org/10.1188/21.CJON.E1-E9.CrossRefPubMed

112.

Londono MC, Reig M, Retoinmuno Multidisciplinary Group. Multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors. Cancers (Basel). 2020;12(11):3446. https://doi.org/10.3390/cancers12113446.CrossRefPubMedCentral

113.

Bouzereau V, Le Caer F, Guardiola E, Scavennec C, Barriere JR, Chaix L, et al. Experience of multidisciplinary assessment of elderly patients with cancer in a French general hospital during 1 year: a new model care study. J Geriatr Oncol. 2013;4(4):394–401. https://doi.org/10.1016/j.jgo.2013.04.006.CrossRefPubMed

114.

Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, et al. Efficacy of platinum rechallenge in metastatic urothelial carcinoma after previous platinum-based chemotherapy for metastatic disease. Oncologist. 2021;26(12):1026–34. https://doi.org/10.1002/onco.13925.CrossRefPubMedPubMedCentral

115.••

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970–6. https://doi.org/10.1093/annonc/mdz127. This article presents the long-term safety and efficacy outcomes of the international phase 3 KEYNOTE-045 trial. Pembrolizumab showed durable and superior clinical benefit in patients with advanced, platinum-refractory urothelial cancer compared with chemotherapy after ≥2 years of follow-up.CrossRefPubMedPubMedCentral

116.

Rosenberg JE, O’Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–600. https://doi.org/10.1200/JCO.19.01140.CrossRefPubMedPubMedCentral

117.

Siefker-Radtke AO, Necchi A, Park SH, Garcia-Donas J, Huddart RA, Burgess EF, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23(2):248–58. https://doi.org/10.1016/S1470-2045(21)00660-4.CrossRefPubMed

Title: Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts
Authors: Daniele Santini
Giuseppe Luigi Banna
Sebastiano Buti
Luca Isella
Marco Stellato
Michela Roberto
Roberto Iacovelli
Publication date: 19-10-2023
Publisher: Springer US
Keywords: Expert Opinion
Expert Opinion
Targeted Therapy
Maintenance Therapy
Urothelial Cancer
Urothelial Cancer
Cytostatic Therapy
Checkpoint Inhibitors
Published in: Current Oncology Reports / Issue 11/2023
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-023-01461-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 11/2023

Incorporation of Palliative Care in Gynecologic Oncology

Exercise as Medicine in Cardio-Oncology: Reducing Health Disparities in Hispanic and Latina Breast Cancer Survivors

Advances in Treatment of Waldenström Macroglobulinemia

Immune-Related Adverse Events in Patients with Lung Cancer

Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma

Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives

Keynote webinar | Spotlight on antibody–drug conjugates in cancer